Amneal Pharma Proxy: Exec Pay & Board Nominee Details

Ticker: AMRX · Form: DEF 14A · Filed: Mar 25, 2025 · CIK: 1723128

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance, board-of-directors

Related Tickers: AMRX

TL;DR

Amneal's proxy is out - check exec pay & board picks for 2024.

AI Summary

Amneal Pharmaceuticals, Inc. filed its definitive proxy statement on March 25, 2025, for its annual meeting on May 6, 2025. The filing details executive compensation, board nominations, and other corporate governance matters for the fiscal year ending December 31, 2024. Key individuals like Chirag Patel and Chintu Patel are listed as members, with compensation data for multiple fiscal years.

Why It Matters

This filing provides crucial insights into how Amneal Pharmaceuticals compensates its top executives and the individuals nominated to oversee the company, impacting investor confidence and corporate strategy.

Risk Assessment

Risk Level: medium — Proxy statements can reveal information about executive compensation, board composition, and shareholder proposals that may indicate potential governance risks or strategic shifts.

Key Numbers

Key Players & Entities

FAQ

What is the total compensation for Chirag Patel and Chintu Patel for the fiscal year 2024?

The filing indicates compensation data for Chirag Patel and Chintu Patel for the fiscal year 2024, with specific amounts detailed within the proxy statement's compensation tables.

Who are the nominated directors for the upcoming annual meeting on May 6, 2025?

The proxy statement lists the individuals nominated for election as directors at the May 6, 2025 meeting, including Chirag Patel and Chintu Patel.

What were the key performance indicators used to determine executive compensation in 2024?

The filing outlines the performance metrics and compensation philosophy used by the Compensation Committee to determine executive pay for the 2024 fiscal year.

Are there any shareholder proposals included in this proxy statement?

The proxy statement will detail any shareholder proposals that will be voted on at the annual meeting, along with management's recommendation.

What is the company's rationale for the proposed executive compensation packages?

The Compensation Discussion and Analysis section of the proxy statement explains the company's reasoning behind the structure and amounts of executive compensation.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 25, 2025 by Chirag Patel regarding Amneal Pharmaceuticals, Inc. (AMRX).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing